MADRID, April 6, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discoveryand development of innovative marine-derived anticancer drugs, today announced that it will host a Research and Development Event in New York on Monday, April 24th, 2017, from 10:30
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The presentation will be webcast simultaneously on the calendar section of the Company's Events Calendar page of the website at http://www.pharmamar.com
A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at http://www.pharmamar.com.
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com
MEDIA CONTACTS : Media Relations Manager (Paula Fernández +34-638-79-62-15 – email@example.com ) and Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!